XELJANZ® (tofacitinib citrate) is a small molecule that selectively targets the JAK pathway
Helps protect against RA, PsA and UC
Efficacy proven by different studies
Review the upcoming events
The Capital – A Wing, 1802, 18th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India.
®Trademark Proprietor: PF Prism C.V.
Licensed User: Pfizer Limited, India
To view the summary of prescribing information for XELJANZ®, please click here.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
Full prescribing information available on request.
JAK, Janus kinase; PsA, psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022